Modulation of mucin secretion using combined polyethylene glycol-propylene glycol topical formulation in a hyperosmotic stress-based explant model.


Journal

Indian journal of ophthalmology
ISSN: 1998-3689
Titre abrégé: Indian J Ophthalmol
Pays: India
ID NLM: 0405376

Informations de publication

Date de publication:
04 2023
Historique:
medline: 10 4 2023
entrez: 7 4 2023
pubmed: 8 4 2023
Statut: ppublish

Résumé

Ocular surface discomfort and dry eye disease are caused by a dysfunctional tear film. The efficacy of lubricating eye drops on the human eye is known, but the compositions may show differential effects on rescuing the tear film. Mucins form a critical layer of the tear film, a reduction of which may be causative for ocular surface conditions. Therefore, it is essential to develop relevant human-derived models to test mucin production. Human corneoscleral rims were obtained from a healthy donor (n = 8) post-corneal keratoplasty and cultured in DMEM/F12 media. Hyperosmolar stress mimicking dry eye disease was induced by exposing the corneoscleral rim tissues to +200 mOsml NaCl-containing media. The corneoscleral rims were treated with polyethylene glycol-propylene glycol (PEG-PG)-based topical formulation. Gene expression analysis was performed for NFAT5, MUC5AC, and MUC16. Secreted mucins were measured by enzyme-linked immunosorbent assay (ELISA) (Elabscience, Houston, TX, USA) for MUC5AC and MUC16. The corneoscleral rims responded to hyperosmolar stress by upregulating NFAT5, a marker for increased osmolarity, as observed in the case of dry eye disease. The expression of MUC5AC and MUC16 was reduced upon an increase in hyperosmotic stress. The corneoscleral rim tissues showed induction of MUC5AC and MUC16 expression upon treatment with PEG-PG topical formulation but did not show significant changes in the presence of hyperosmolar treatments. Our findings showed that PEG-PG-based topical formulation slightly alleviated hyperosmolar stress-induced decrease in MUC5AC and MUC16 gene expression that is encountered in DED.

Identifiants

pubmed: 37026305
pii: IndianJOphthalmol_2023_71_4_1582_373505
doi: 10.4103/IJO.IJO_2855_22
pmc: PMC10276745
doi:

Substances chimiques

Mucins 0
Propylene Glycol 6DC9Q167V3
Polyethylene Glycols 3WJQ0SDW1A
CA-125 Antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1582-1586

Déclaration de conflit d'intérêts

None

Références

Gene Ther. 2013 May;20(5):467-77
pubmed: 22809996
Mol Biol Cell. 2010 Oct 1;21(19):3459-74
pubmed: 20685965
Mol Vis. 2011 Jan 12;17:113-26
pubmed: 21245952
Exp Eye Res. 2004 Mar;78(3):379-88
pubmed: 15106916
J Ocul Pharmacol Ther. 2012 Jun;28(3):264-70
pubmed: 22304618
Prog Retin Eye Res. 2016 Jul;53:140-174
pubmed: 27094372
Prog Retin Eye Res. 2019 Jul;71:68-87
pubmed: 30471351
Curr Genomics. 2010 Dec;11(8):584-90
pubmed: 21629436
Adv Sci (Weinh). 2021 Aug;8(16):e2100841
pubmed: 34184839
J Immunol. 2002 Nov 15;169(10):5477-88
pubmed: 12421923
Int J Mol Sci. 2017 Jun 29;18(7):
pubmed: 28661456
Clin Transl Sci. 2021 Jan;14(1):288-298
pubmed: 32896986
Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2602-9
pubmed: 9856770
Ophthalmologica. 2002 Sep-Oct;216(5):368-71
pubmed: 12424406
Dtsch Arztebl Int. 2015 Jan 30;112(5):71-81; quiz 82
pubmed: 25686388
Int J Mol Sci. 2020 May 15;21(10):
pubmed: 32429217
Sci Rep. 2015 May 21;5:10248
pubmed: 25996902
BMJ Open Ophthalmol. 2021 Apr 8;6(1):e000697
pubmed: 33907713
Cornea. 1998 Nov;17(6):584-9
pubmed: 9820935
J Indian Med Assoc. 2012 Nov;110(11):789-94
pubmed: 23785913
Br J Ophthalmol. 2012 Oct;96(10):1310-5
pubmed: 22914501
Clin Ophthalmol. 2018 Jul 12;12:1237-1243
pubmed: 30034217
Ocul Surf. 2007 Apr;5(2):75-92
pubmed: 17508116
Curr Pharm Des. 2016;22(28):4470-90
pubmed: 27296759
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4390; 4391-8
pubmed: 17898256
High Alt Med Biol. 2008 Winter;9(4):327-34
pubmed: 19115918
Ophthalmology. 2012 Dec;119(12):2471-8
pubmed: 23009892
Middle East Afr J Ophthalmol. 2017 Oct-Dec;24(4):202-206
pubmed: 29422755
Clin Ophthalmol. 2014;8:157-64
pubmed: 24403819
Invest Ophthalmol Vis Sci. 2002 Apr;43(4):1004-11
pubmed: 11923240
Clin Ophthalmol. 2009;3:405-12
pubmed: 19688028
Ocul Surf. 2007 Apr;5(2):93-107
pubmed: 17508117
Clin Ophthalmol. 2021 Jun 09;15:2421-2435
pubmed: 34135570
PLoS One. 2020 Nov 24;15(11):e0242617
pubmed: 33232357
Ocul Surf. 2013 Oct;11(4):246-58
pubmed: 24112228
Indian J Ophthalmol. 2005 Jun;53(2):87-91
pubmed: 15976462
Invest Ophthalmol Vis Sci. 2008 May;49(5):1827-35
pubmed: 18436816
Ann Trop Med Parasitol. 2010 Apr;104(3):247-55
pubmed: 20507698

Auteurs

Trailokyanath Panigrahi (T)

GROW Research Laboratory, Narayana Nethralaya Foundation, Bengaluru, Karnataka, India.

Edwin James (E)

Government Medical College, Paripally, Kollam, Kerala, India.

Pooja Khamar (P)

Department of Cornea and Refractive Surgery, Narayana Nethralaya, Bengaluru, Karnataka, India.

Bhavya Gorimapalli (B)

Department of Cornea and Refractive Surgery, Narayana Nethralaya, Bengaluru, Karnataka, India.

Sharon D'Souza (S)

Department of Cornea and Refractive Surgery, Narayana Nethralaya, Bengaluru, Karnataka, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH